Experimental Description

0080-EX-PL-2002 Text Documents

Medtronic Inc

2002-04-22ELS_55460

                                                                  Exhibit 1
                                                            Medtronic, Inc.
                                                               FPCC Form 442




                            NARRATIVESTATEMENT


     On July 28,   1997,   Medtronic,   Inc.,   a world leader in the
development of medical implant devices, filed a petition urging the
Commission to issue a notice of proposed rule making calling for
the creation of the Medical Implant Communications Service ("MICS")
in the 402—405 MHz band under Part 95 of the Rules.  See Petition
for Rule Making filed by Medtronic, Inc., RM No. 9157.  A copy of
that petition is attached for the staff‘s convenience.

     MICS operations would provide for the transmission of data to
and from implanted medical devices such as cardiac pacemakers and
defibillators via high speed (100 kbps or more) short—range ultra
lower power (25 microwatts) wireless links.  MICS systems would
replace the cumbersome, slow—speed inductive coupling technology
now used.  By this application, Medtronic is requesting an
experimental radio license to develop and test MICS systems.

     MICS requires a power of only —16 dBm (25 uW) EIRP to be
effective and will be used largely indoors usually in urban areas,
which virtually eliminates the potential for MICS to interfere with
other services.

     The experimentation will use digital FM modulated signals with
bandwidth which would not extend beyond the specific frequencies
requested.  The 300 kHz necessary bandwidth is the maximum that is
needed given the maximum data rate and modulation scheme, which
assumes 1 bit/Hz and 50 kHz peak frequency Gdeviation. As shown in
Appendix C of the attached Petition for Rule Making, operation at
the requested power level is not expected to cause interference to
existing licensees.

     The equipment to be tested will come from multiple
manufacturers. The experimentation would involve a maximum of 10
programming units (base stations) and 100 implants (mobiles) .

     Medtronic understands that the FCC permits (1) companies to
enter into agreements and contracts to manufacturer new products;
(2) manufacturers to sell, but not deliver, products on a




 ie


conditional basis to wholesalers and retailers; (3) entities to
operate prototype devices for, among other things, compliance
testing, demonstration at trade shows and other exhibitions with
appropriate notices displayed; and (4) companies to evaluate
product performance and customer acceptability at the
manufacturer‘s facilities or at certain non—residential sites
during the developmental,     design, and pre—production stages.   See
Marketing Rule Revisions,     § 2.803; Part 15 Revisions, 6 FCC Red
1683,   1685   (1991) .


     Notwithstanding these general rules, however, the FCC requires
entities to seek experimental or other authorization (1) to operate
devices in frequency bands that normally are licengsed and (2) to
use products in residential environments.  Such authority may be
granted under the FCC‘s experimental rules set forth in Part 5 of
the Code of Federal Requlations, 47 C.F.R. Part 5 (1996) .

     Accordingly, Medtronic seeks an experimental license to
conduct studies in licensed bands and in residential environments
as permitted under Section 5.202 (j) of the Commission‘s rules.  47
C.F.R. § 5.202 (j) (1996). Those rules permit companies to conduct
such studies,     as well as to distribute,   provided that:   (1)
participants are advised that the service or device is granted
under experimental authority and is strictly temporary; and (2) the
devices are owned by the licensee.  Grant of such authority would
allow Medtronic to study products under experimentation.

     As a final matter, please note that the experimentation
proposed in this application employs ultra low power and thus is
categorically excluded from the FCC‘s requirements associated with
human exposure to RF radiation.  Thus, the proposed operation would
not have a significant environmental effect under Section 1.1307 of
the FCC‘s rules.

     Although no human implantation will be conducted under the
requested authorization, the grant of this application will allow
Medtronic to develop an innovation that would greatly improve the
utility of implanted medical devices and enhance the quality of
life of patients.  Accordingly, Medtronic submits that a grant will
serve the public interest, convenience, and necessity.



Document Created: 2002-04-22 13:22:46
Document Modified: 2002-04-22 13:22:46

© 2025 FCC.report
This site is not affiliated with or endorsed by the FCC